



**Freedom of Information Request**

**Ref: UHB 19-555**

1 October 2019

By Email

Dear Sir/Madam

Thank you for your request for information under the Freedom of Information Act 2000. The Trust's response is as follows:

1. Does your trust treat adult multiple myeloma [MM] ?  
Yes.  
- if you refer your multiple myeloma patients to another centre, please state which.  
N/A.
2. If yes, then how many multiple myeloma patients, have been treated in the past 6 months with the following; (NB. If a patient has received a combination regimen with two or more of the drugs listed they have been included in both categories)
  - Bortezomib [Velcade]: 24
  - Carfilzomib [Kyprolis]: 1
  - Ixazomib [Ninlaro]: 3
  - Lenalidomide [Revlimid]: 15
  - Daratumumab [Darzalex]: 16
  - Melphalan, prednisolone and thalidomide (known as MPT): 1
  - Cyclophosphamide, thalidomide and dexamethasone (known as CTD): 4
  - Pomalidomide [Imnovid]: 4
3. Over the past 6 months [latest possible], how many chronic lymphocytic leukaemia (CLL) patients have you treated?  
56 with Systemic anti-Cancer Therapy (SACT).
4. If possible, how many CLL patients treated were new to therapy in the past 3 months?  
The Trust is not able to determine patients that are "new to therapy".
5. How many chronic lymphocytic leukaemia patients, have been treated in the past 6 months with the following;

- Fludarabine (Fludara), cyclophosphamide (Cytosan), and rituximab (known as FCR): 1
- Bendamustine and rituximab (known as BR): 2
- Ibrutinib [Imbruvica]: 27
- Chlorambucil: 2
- Venetoclax: 11
- Obinutuzumab: 6
- Idelalisib: 1
- Fludarabine and rituximab (known as FR): 0
- High-dose prednisone and rituximab: 0
- Pentostatin (Nipent), cyclophosphamide, and rituximab (known as PCR): 0
- Alemtuzumab (Campath) with rituximab: 0

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Trust Secretary  
 University Hospitals Bristol NHS Foundation Trust  
 Trust Headquarters  
 Marlborough Street  
 Bristol  
 BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

#### Publication

Please note that this letter and the information included/attached will be published on our website as part of the Trust's Freedom of Information Publication Log. This is because information disclosed in accordance with the Freedom of Information Act is disclosed to the public, not just to the individual making the request. We will remove any personal information (such as your name, email and so on) from any information we make public to protect your personal information.

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely

**FOI Team**  
**UH Bristol NHS Foundation Trust**